Sanmeet Deo

These medicines are both amplifying a therapeutic process the person is going through.

And then also the medicines are actually working on your brain too, biologically, and doing things there.

So you get a two-for-one with this treatment.

Whereas, let's say antidepressants, which Will kind of mentioned really briefly, those are working on your brain.

You're not pairing them with therapy in the sense where that's enhancing the therapy.

So this is very unique in that way.

Well, there's different places you could be investing.

Obviously, you can invest in the biopharm companies that are putting out the drugs.

And that's kind of the most straightforward thing to be investing in.

I mean, I think one thing is, you know, if you're not a biopharm investor, a lot of drugs don't get through their application in phase three.

And that's just the reality.

So there's that.

You have to look out for that.

We had a rejection for MDMA in 2024.

Now, I think the positive thing that Compass is going for them is that they did their study in a very different way than the previous study was done on MDMA.

The MDMA study had one component to it that is a little challenging for the FDA to understand, which is the therapy.

It was a very embedded part of the actual research.

Whereas they really tried to look at the drug effect more so isolated in the psilocybin studies and not look at the therapy as much.

And they call it psychological support.

So that's a very positive thing to be aware of.